Glycine is a co-agonist of glutamate at the NMDA receptor. Glycine transporter 1 (GlyT1) inhibitors are reported to be potential therapeutic agents for schizophrenia.
INTRODUCTION
The N-methyl-D-aspartate (NMDA) receptor regulates many critical functions including synaptic plasticity and memory. 1, 2 Deficits in glutamate transmission at the NMDA receptor have been reported to be important in the pathophysiology of schizophrenia. [3] [4] [5] Glycine acts as a required co-agonist along with glutamate at the NMDA receptor, 6, 7 and its extracellular concentration is controlled by the glycine transporters, mainly by glycine transporter type 1 (GlyT1). [8] [9] [10] Thus, imaging of GlyT1 may be a useful tool in evaluating the importance of this site in the etiology of neuropsychiatric syndromes as well as the efficacy of drugs targeting GlyT1.
Several radiotracers have been developed to image GlyT1 with positron emission tomography (PET), including 11 C-GSK931145, 11 11 C-RO5013853, 12 and 18 F-MK6577. 13,14 18 F-MK6577 is a relatively new and promising tracer that has been shown to be superior to 11 C-GSK931145 with faster kinetics and higher specific binding signal, as well as better counting statistics afforded by its 18 F radiolabel. 14 Positron emission tomography imaging studies with 18 F-MK6577 have been reported in nonhuman primates 13 and humans recently. 15 Human studies indicated the absence of a reference region for this GlyT1 radiotracer. 15 Positron emission tomography studies are performed at tracer doses, i.e., with minimal occupancy of the target by the radiopharmaceutical. The strength of signal provided by a radiotracer, as measured by the binding potential (BP), is determined by the target concentration (B max ) and the radiotracer's affinity to the target (1/K d ), i.e., BP = B max /K d . However, these two parameters, B max and K d , cannot be separated in vivo under normal 'tracer' imaging conditions. Thus, a number of methods have been developed to estimate B max and K d separately with imaging experiments. At first, multiple bolus injections of a radiotracer with a range of specific activities were made and pseudo-equilibrium measurements were used to determine B max and K d. 16 Later, multiple bolus plus infusion (B/I) administrations of radiotracer with varying specific activities were introduced to establish 'true' equilibrium measurements. 17 Alternatively, several groups have conducted multiple bolus injections (tracer with high and low specific activity or unlabeled compound alone) in one experiment, and made use of the full time course of data to estimate all kinetic parameters including K d.
18,19
We designed a novel, multi-infusion paradigm to measure the in vivo K d of a radioligand and to image the target density (B max ). The defining experimental features that differentiate this method from previous approaches are (1) multiple separate bolus plus infusion administrations were carried out within one continuous PET scan and (2) no reference region was needed; instead, the nondisplaceable distribution volume (V ND ) was treated as a parameter to be estimated. To produce B max images, a computationally practical iterative linear/nonlinear alternating fitting algorithm was developed. Here, we report the results from the application of this new paradigm to 18 F-MK6577 in baboons.
MATERIALS AND METHODS Radiochemistry 18
F-MK6577 was synthesized by reaction of its chloro precursor with K 18 F in DMSO at 200°C for 10 minutes, as previously reported. 14 The final tracer product was produced in high radiochemical yield (20.8 ± 3.8%, decay-uncorrected, at the end of synthesis), high specific activity (396 ± 196 MBq/ nmol), and high chemical and radiochemical purity (4 95% for both, n = 7).
Multiinfusion Injection Experiment Design
The aim of this study was to estimate GlyT1 B max and the in vivo K d of MK6577 using equilibrium conditions. The equilibrium equation for bound ligand, in the absence of endogenous neurotransmitter is
where B is the bound ligand concentration (nmol/L) and M FP is the free mass concentration of the ligand in plasma (nmol/L) that serves as a surrogate for free concentration in tissue at equilibrium. To estimate B max and K d , multiple observations of B and M FP are required. Thus, our experiment design tried to achieve as many tracer-receptor equilibrium periods as possible in one scan. Accordingly, the bolus plus infusion (B/I) approach 20 was employed using multiple infusions during the scan. One infusion was used for the labeled (hot) tracer, and two later infusions were used for unlabeled (cold) compound to occupy two different levels of the target. This design took advantage of 18 F (half-life: 109.8 minutes) labeling and the fast kinetics of 18 F-MK6577. Based on initial test studies, the final multi-infusion experimental design consisted of one 300-minute 18 F-MK6577 B/I with two separate 90-minute B/I with increasing mass doses of unlabeled MK6577 beginning at 120 and 210 minutes, respectively, as shown in Figure 1 .
To implement this design, a number of factors must be determined, specifically the bolus injection constant (K bol , minutes) 20 and the infusion rates of cold compound for the second and third stages (I cold1 and I cold2 , nmol/kg per minute). Therefore, bolus injection experiments were performed in advance to understand the basic kinetic features of 18 F-MK6577 in baboon. Let C bolus (t) (Bq/mL) be the time-activity curve (TAC) for any tissue (T) region of interest (ROI) or the plasma (P) after bolus administration, and let g(t) (g/mL) be the corresponding normalized free tracer concentration, by correcting C bolus (t) for free fraction f P , animal weight (W, kg), and the injected bolus dose (D, kBq), then
The normalized ROI TAC, h T (t) (g/mL), after a B/I injection can be predicted from g T (t), 20 where T inf is the infusion length (minutes):
We evaluated h T (t) for the brainstem, cerebellum, and cingulate cortex while varying K bol from 60 to 120 minutes and visually determined a K bol value that produced equilibrium most rapidly. Data from four bolus injections were used, and K bol was chosen to be 90 minutes. Assuming body kinetics are unaffected by mass dose, the g P (t) curves can be used to predict radioactivity or mass concentration in plasma at equilibrium after B/I administration based on an infusion rate I. We define clearance rate (CL, L/kg per minute) as the reciprocal of the integral of the bolus response function.
To estimate the integral to infinity, the tails of the bolus curves were fitted to an exponential function. Based on four bolus studies, CL was determined to be 0.22 ± 0.07 L/kg per minute. Given a hot constant infusion with rate I hot (kBq/kg per minute), using the plasma bolus response function g P (t) in equation (2) and the definition of clearance in equation (4) , the predicted equilibrium free plasma radioactivity value C FP,eq (Bq/mL) would be:
We assumed that the cold compound had the same response as the hot tracer, i.e., that the system was linear and the cold compound did not saturate any biologic processes such as clearance or metabolism. Then, upon delivering a constant infusion rate of I cold (nmol/kg per minute), the predicted equilibrium free plasma mass concentration M FP,eq (nmol/L) would be:
The injected cold mass doses were estimated to reach predefined occupancy levels. The receptor occupancy (r), the ratio of bound to total receptor concentration, can be calculated from the equilibrium equation (1) as follows:
Rearranging (7) into
yields the dependence of M FP,eq on the targeted value of r. Since we had no knowledge of the in vivo K d , the in vitro inhibition constant (K i , 1.15 nmol/L 13 ) was used in equation (8) . Combining (6) and (8), the desired infusion rate for the unlabeled compound is:
Magnetic Resonance Imaging
Magnetic resonance (MR) images were acquired on a Siemens Magnetom 3.0T Trio scanner, using an extremity coil. T1-weighted images were acquired in the coronal plane with a spin echo sequence. The MR images were stripped of the skull and muscle 21 so that only the brain remained in the image. The image dimension was 176 × 176 × 176 voxels with a voxel size of 0.55 × 0.55 × 0.54 mm 3 .
Positron Emission Tomography Imaging Procedures
Positron emission tomography experiments were performed according to a protocol approved by the Yale University Institutional Animal Care and Use Committee. Two female baboons (18.4 ± 6.3 kg, 8.5 ± 0.5 years) underwent two scanning sessions each on the HR + PET scanner (Siemens Medical Solutions, Knoxville, TN, USA). The baboons were sedated with a 10 mg/kg intramuscular dose of ketamine approximately 2 hours before the radiotracer injection. Once stable, animals were transported to the scan area and anesthesia was maintained on 1.5% to 2.5% isoflurane. A catheter was placed in the femoral or radial artery for blood pressure monitoring and arterial blood sampling. Two syringe pumps (PHD 2000 Programmable Pump; Harvard Apparatus, Holliston, MA, USA) were used for the injections, one for the hot tracer and the other for the two cold doses. At each injection stage, a 3-minute high rate injection was used to deliver the bolus portion, then a lower rate was used to maintain the infusion. Throughout the 300-minute scan, heart rate (HR), respiratory rate, body temperature, end tidal pCO 2 , oxygen saturation, and blood pressure were monitored a minimum of four times per hour, more frequently immediately after injection of the tracer and cold compound doses. After administration of the cold compound, very slight changes were noticed, i.e., a decrease in HR, and increases in respiratory rate, blood pressure, and body temperature. For the bolus components, K bol = 90 minutes for all three injections. Three equilibrium periods were 60 to 120, 150 to 210, and 240 to 300 minutes.
A summary of the hot and cold infusion parameters is provided in Table 1 . The designed occupancies were intentionally chosen to be high to provide reliable estimates of V ND as well as B max and K d . For each experiment, a 6-minute transmission scan was obtained immediately before tracer injection, followed by a 300-minute emission scan in 3D mode initiated at the start of tracer administration. List-mode data were reformatted into 69 frames and reconstructed with Fourier rebinning and 2D-OSEM. 22 Image reconstruction included corrections for attenuation, dead time, random counts, and scatter. The image size was 128 × 128 × 63 voxels, with an in-plane voxel size of 2.06 mm and an axial voxel size of 2.43 mm.
Free Fraction Measurement, Metabolite Analysis, and Generation of Plasma Input Function
The free fraction in plasma (f p ) was measured using an ultrafiltration-based method with a reference blood sample taken immediately before tracer injection to which was added a small amount (~3.7 MBq) of the radiotracer. After 10 minutes incubation at room temperature, the sample was centrifuged at 2,930 g for 5 minutes and plasma aliquots (0.3 mL) were loaded into the reservoir of the Millipore Centrifree micropartition device in triplicate and centrifuged at 1,228 g for 20 minutes. Free fraction was determined from the ratio of the radioactivity concentration in the ultrafiltrate to that in plasma.
Arterial blood samples were collected during each scan. Radioactivity concentration of whole blood and plasma samples was measured with a cross-calibrated gamma well counter (1480 WIZARD; PerkinElmer, Waltham, MA, USA). The tail portion of the total plasma concentration curve was fitted to a 3-exponential function. In addition, selected samples taken at 3, 8, 15, 30, 60, 90, 120, 180, 210, 270 , and 300 minutes were analyzed to assess the unchanged parent fraction using the automatic column-switching HPLC method. 23 After separation from red blood cells by centrifugation (2,930 g for 5 minutes), plasma samples were mixed with 8 mol/L urea and then filtered through a 1.0-μm Whatman 13 mm GD/X syringe filter (GE, Florham Park, NJ, USA). Up to 5 mL of plasma filtrate was then injected onto the HPLC system equipped with a Gemini-NX C18 analytical column (250 × 4.6 mm, 5 μm, Phenomenex, Torrance, CA, USA), eluting with 35% acetonitrile in 0.1 mol/L ammonium formate at a flow rate of 1.65 mL/min. The parent compound retention time was 11 minutes. Fractions of the HPLC eluate were collected and counted for radioactivity in the gamma counter. The sample recovery rate, extraction efficiency, and HPLC fraction recovery were monitored. The parent fraction was calculated as the ratio of the sum of radioactivity in fractions containing the parent tracer to the total amount of radioactivity collected. The parent fraction curve was fitted to an integrated γ-function. The data were also corrected for the time-varying extraction efficiency of radioactivity in the filter and normalized to the extraction efficiency determined from the reference plasma sample. The final plasma input function was calculated as the product of the fitted total plasma curve, fitted parent fraction curve, and fitted extraction efficiency curve.
Positron Emission Tomography Image Analysis
The PET-MR registration consisted of two steps: (1) PET images were aligned to each baboon's MR via a 6-parameter rigid registration with the Multi-Transform Method 24 to generate the optimal transformation to map the PET dynamic data into the baboon's MR image space; (2) An affine linear+nonlinear registration 25 was performed using each MR image and a high-resolution baboon MR template. Regions of interest were delineated on the MR template and then mapped back to PET space via these two transforms to compute the TACs for ROI analysis. Defined ROIs included brainstem, caudate, cerebellum, cingulate, frontal cortex, globus pallidus, insula, nucleus accumbens, occipital cortex, pons, putamen, and thalamus.
The entire PET scan was divided into three infusion stages: 0 to 120 minutes (hot only), 120 to 210 minutes (hot+cold 1), and 210 to 300 minutes (hot+cold 2) as shown in Figure 1 . The equilibrium period of each stage was chosen by inspecting the constancy of ROI TACs and the input function data, i.e., by performing linear fitting and examining the slope. Positron emission tomography images were averaged during each equilibrium period and resliced into MR template space to align different scans for voxelwise analysis.
Distribution volume (V T ) for each image voxel or ROI was determined at each equilibrium period as
where C T and C P denote the average concentration in voxel/ROI and plasma, respectively, during the equilibrium period.
Estimation of B max and K d
Since there is not an apparent region devoid of specific binding for 18 F-MK6577, V T values were fitted on a regional and voxel level to equation (11) to estimate K d , B max , and V ND values:
Here, SA was the net specific activity in unit of kBq/nmol. This value was calculated from the ratio of the infusion rates of hot and cold molecules, accounting for the total cold mass from the hot and cold infusions. Equation (11) assumes that the free tracer concentration in tissue and plasma is identical at equilibrium. Weights were used in nonlinear fitting as follows:
Here V T is calculated as the ratio of the average of the tissue concentration values in a region with N vox voxels to the plasma concentration (for voxel analysis, N vox = 1). The reconstructed voxel values are approximated as the product of the Poisson counts from voxel j (X j ) multiplied by a decay correction term (D) and a scale factor (A) to account for attenuation, efficiency, etc. The variance of V T can then be calculated by assuming Poisson statistics. Algebraic rearrangement leads to the formula for weights w, which are inversely proportional to the variance. In vivo B max and
The analysis was performed using seven data groupings: four with data from a single day experiment with three equilibrium periods (B1_D1 = baboon 1 on day 1, B1_D2, B2_D1, B2_D2), two with each individual baboon's data from both experimental days together (B1, B2, 6 equilibrium periods each), and one with all data (POOLED, 12 equilibrium periods).
Individual regional B max values or B max images were determined, and K d was assumed to be identical throughout the brain. Two analyses were performed with each data set using different assumptions for V ND : (1) UND, which constrained V ND to be a constant across ROIs or voxels, i.e., Uniform Non-Displaceable volume of distribution and (2) NUND, where V ND could be Non-Uniform, i.e., different among regions and voxels and thus an additional independent parameter. Fits were performed at both ROI and voxel levels.
For regional analysis, with 12 regions, the total number of parameters to be estimated was 14 (1 K
For UND, the first step was a linear component that used fixed global values of K d and V ND and fitted for a B max image (indexed with j) with~1 M independent fits of one parameter with up to N = 12 points each (indexed with i). In this process, there was no crosstalk between voxels, and since K d and V ND were fixed, the fitting was linear. For each voxel j, the equations for the linear regression of independent variable x i versus dependent variable y i,j to estimate the slope B max,j are
The second step was a nonlinear component, which fixed the B max image, and fitted for K d and V ND from up to 12 M measurements using a Marquardt-Levenberg algorithm. Similarly for NUND, the linear step fixed K d and fitted for B max and V ND images with~1 M independent linear fits, i.e., for each voxel j. Each fit contains two parameters with up to 12 data points.
The nonlinear step fixed the B max and V ND images, and fitted for K d from up to~12 M measurements. Average values from ROI fits across experiments were used for the initial guesses. The linear and nonlinear steps were repeated until either of the following conditions was satisfied: (1) the residual sum of squares started to increase or (2) the percentage change in K d over one iteration was less than 0.01%. For analyses using POOLED or single-baboon data, 5 to 8 iterations were required for convergence. On a standard workstation, the full ROI analysis required o 10 seconds and one iteration of the voxel analysis (M =~0.8 M) required~1.5 minutes.
RESULTS

Free Fraction and Metabolite Analysis
Plasma-free fraction varied slightly across day and baboon, with values of 0.10 ± 0.01 (n = 4). Parent tracer fractions were 36 ± 5% and 24 ± 3% at 90 and 300 minutes, respectively (n = 4).
Representative Images and Time-Activity Curves Figure 2 displays transverse, coronal, and sagittal views of the uptake of 18 F-MK6577 at baseline (average of 60 to 120 minutes) and under high cold mass dose conditions (average of 240 to 300 minutes, designed receptor occupancy of 87%). Brain images showed good uptake with the expected distribution of highest concentrations in the brainstem and pons, medium in the thalamus and cerebellum, and low uptake in the striatum and cortical regions. Figure 3 shows sample TACs of three representative ROIs (brainstem, cerebellum, and cingulate gyrus) and the fitted input function in experiment B2_D1. In each stage, equilibrium was reached rapidly. Equilibrium periods were chosen to be 60 to 120, 150 to 210, and 240 to 300 minutes, as denoted in gray in Figure 3 . The percent change per hour of the input function during the three periods was − 3.3 ± 2.2, − 7.5 ± 3.0, and +2.8 ± 6.1, respectively. For the ROI TACs, average values for three representative regions were − 3.5 ± 4.5%, − 4.9 ± 7.7%, and +1.4 ± 9.6%/hour. These slopes were averaged across scan days.
Occupancies
To assess the accuracy of the planned infusion parameters (Table 1) , we used the occupancy plot 26 to estimate occupancy in each condition. Compared with the designed occupancy, the fitted values were lower by 17 ± 9%. This suggests that the actual in vivo K d is somewhat higher than the in vitro value of 1.15 nmol/L.
Region of Interest Analysis Results
Parameter estimates from ROI analysis based on UND and NUND assumptions are listed in Tables 2 and 3 , respectively. The value of K d was in the range of 1 to 2 nmol/L, which was in good agreement with the in vitro K i value of 1.15 nmol/L used in the initial experimental design. This good agreement is not surprising, since the TACs in Figure 3 were well matched with theoretical predictions. If V ND was allowed to vary across regions (NUND), then K d increased somewhat compared with the UND values. Similarly, the V ND values estimated with the NUND assumption were near the value obtained under UND. The percentage differences between the UND and NUND values are shown in Table 3 , with a maximum difference of 26%.
Across analysis methods, B max was highly correlated to K d , i.e., data groupings that produced larger K d values also gave larger B max values. This is not unexpected, as small errors in the highoccupancy data (stages 2 and 3) will produce errors in both B max and K d , while the ratio BP F = B max /K d is unaffected, since this value is defined mostly from the high specific activity data (stage 1). BP F values were more consistent, either derived individually or jointly, compared with B max or K d values. GlyT1 B max values of 18 (UND) and 30 (NUND) nmol/L in the cingulate cortex, as estimated from the POOLED data set, agreed reasonably well with the in vitro B max value of 570 fmol/mg protein, or approximately equivalent to 28 to 57 nmol/L in human medial frontal cortex. 27 Comparing results from NUND and UND analyses for the POOLED data, the correlation of 12 regional B max values was excellent (R 2 = 0.99), but the slope was 1.48 [B max (NUND) = 1.48 B max (UND)], consistent with the ratio of K d values, i.e., 1.87/ 1.28≈1.46. The BP F estimates showed excellent agreement between UND and NUND assumptions, with R 2 = 0.99 and slope = 1.02. The F-test showed that NUND was a better assumption (F 11,119 = 3.01, p = 0.0046), suggesting that nondisplaceable binding is not uniform throughout the brain. Figure 4 shows the results of voxel-based analyses with all parametric images from the POOLED analysis. In general, the statistical quality of the parametric images was extremely high. Under the UND assumption, one V ND value was produced for the whole brain, but for visual convenience, it was shown as a parametric image with uniform value of 2.35. NUND V ND ranged from 1.84 to 2.99 (5th to 95th percentile). Higher V ND values appeared to concentrate in the white matter and cerebrospinal fluid (CSF, see Discussion).
Voxel Analysis Results
Regions of interest were applied to the parametric images to extract average values of B max and V ND to compare with their counterparts from ROI analysis under NUND. Both ROI and voxelbased analysis gave K d values of 1.87 nmol/L from the POOLED analysis, and among 24 variables (12 regional B max and 12 regional V ND ), the maximum absolute difference between ROI and voxelbased values was 4.8% and the average of absolute differences was 2.1%. The regression between ROI and voxel values gave R 2 = 0.91 with slope = 1.01 for V ND , and R 2 = 0.99 with slope = 0.97 for B max .
Given the statistical improvement of NUND over UND from the F test and the overall consistency of ROI and voxelwise analyses, the final estimate of K d was 1.87 nmol/L, which was highly consistent with the reported in vitro values of IC 50 = 1.99 nmol/L and K i = 1.15 nmol/L. 13 
DISCUSSION
In this study, we have shown a new approach for measurement of B max and in vivo K d of a radiotracer. This approach used one continuous B/I administration of the labeled tracer and two infusions of its unlabeled counterpart. An iterative linear/ nonlinear alternating fitting method was used, which involved global constraints on K d and optionally on V ND. This allowed voxel-based analysis to be computationally practical, to produce [16] [17] [18] [19] 28 First, multiple (three in this study) B/I injections were performed during one continuous scan, instead of multiple scans, taking advantage of the fast kinetics of this tracer. Second, this approach was applied to a target where no suitable reference region was present, and V ND was treated as an additional parameter to be estimated in the analysis.
In our analysis, several assumptions were made. First, we assumed that K d is identical throughout the brain. This assumption is generally accepted, unless there is evidence of multiple binding sites in different regions. Note that even if the tracer binds to one site throughout the brain, different levels of endogenous glycine could cause differences in apparent K d throughout the brain (see below). Second, we allowed for nonuniform V ND across regions. This is an unusual assumption in the receptor imaging literature, usually because there are not sufficient data to prove otherwise. With our baboon data, we were able to show higher V ND in whitematter regions. Such a difference is not unexpected, due to the different lipophilicity of white matter compared with gray matter, which can greatly affect partitioning of lipophilic tracers. Finally, we made specific simplifying assumptions in the modeling with regard to (1) cold and hot MK6577 concentrations reaching a constant ratio equaling the cold:hot infusion rate ratio and (2) negligible effect of residual cold MK6577 from the first cold dose. The impact and validity of these assumptions were evaluated by simulation (see below).
Here, we have used B max to identify the concentration of GlyT1 without taking into account any occupancy of GlyT1 by glycine. For baseline scans, this term should more properly be denoted as B avail . However, with subsequent blockade by mass doses of MK6577, the fraction of receptors occupied by glycine will decline. Assuming no change in free glycine during these experiments, strictly we would estimate the total transporter (B max ) but the estimate of K d would be increased by the presence of glycine to a
where C Gly is the glycine concentration and
As mentioned above, we assumed that K d is uniform throughout the brain, a common assumption used in PET studies. This is based on the specific assumptions that there is one specific binding target for the tracer, it exists in only one affinity state, and occupancy of GlyT1 by glycine is uniform throughout the brain. In principle, our analysis could have been extended to perform a regional (or even voxelwise) estimation of K d . However, reliable estimates of K d can only be obtained in regions with high B max . Further, given the need to also determine V ND , we believe nonuniform K d analysis would be better suited for a system with accurate reference region data.
In conventional cases where a reference region exists, researchers explicitly or implicitly assume V ND to be equal to V T in the reference region, and assume it to be constant throughout the brain. For GlyT1, based on the reported human study 15 and our current findings, there is no appropriate reference region for 18 F-MK6577. Thus, in our current analysis, there were three parameters to estimate: B max , K d , and V ND . The computational demands of the voxelwise approach were addressed by the proposed iterative linear/nonlinear alternating fitting method. This approach gave consistent results between ROI and voxel fits, and generated high quality B max images.
We evaluated the uniformity of V ND by allowing it to vary on a regional or voxel level. Based on the result of the F-test from the ROI analysis comparing fits with uniform versus non-uniform V ND , nonuniform V ND was indicated by the data. One concern in using the F test was that the dependent variables in the fit were V T values for each ROI, and these values had correlated noise due to the use of the same plasma data. The parametric V ND images (Figure 4) showed higher values mainly in CSF and white matter. Due to the limited resolution of the HR+ scanner, careful evaluation of V ND uniformity should also include partial volume correction.
Voxelwise analysis was performed on all brain voxels, based on a mask generated from the MR template. Therefore, this analysis included regions not included in the ROI analysis, such as white matter and CSF. Thus, data from those regions contributed to K d (and global V ND ) estimation. Note, however, that the parametric images showed CSF and white matter B max values were low, consistent with little or no GlyT1 in these regions. Regions with low B max values will have only a minor effect on K d estimation, since the V ND term will dominate the measurement (see equation (11)).
In comparison with our method that only used equilibrium data, Delforge and his colleagues employed an approach that used all data to estimate in vivo K d . Briefly, they gave multiple bolus injections with hot and/or cold compound during one experiment, and fitted the entire TAC to the full nonlinear differential equations for hot and cold compounds. This allowed the estimation of the association and disassociation rate constants, k on and k off , and the determination of K d. 18, 19 That analysis required the assumption that the entire time course of cold plasma concentration could be calculated by scaling plasma data from a hot injection. In comparison, our paradigm used B/I injections to reach equilibrium, and used only the equilibrium concentrations (equation (11)), i.e., it used less data and estimated less parameters. Further, the new approach depends only on the assumption that hot and cold concentrations reached a constant ratio during the equilibrium periods, i.e., a constant ratio of hot-tocold is not assumed during the approach to equilibrium. This assumption allowed us to deduce the cold ligand concentration in plasma by scaling the hot concentration by the ratio of infusion rates of cold and hot compounds.
To evaluate the validity of our equilibrium assumption, we performed a simulation using a nonlinear nontracer compartmental model as in the multi-injection method. 19 Since the second and third infusions in our study were cold-only infusions, we had to assume that the entire time course of a cold-only bolus injection could be inferred by scaling the time course of a bolus hot injection. This latter assumption is challenging since the delivery of a high mass dose will affect the whole-body distribution volume, and thus alter uptake and clearance kinetics of the compound. Based on the 2-compartment model fits to the baseline curves (0 to 120 minutes), and using the B max value obtained from our analysis, we generated a set of ideal parameters (K 1 , k 2 , k on , k off , and B max ). We then used the four measured input functions, from which the cold input functions were generated by scaling the hot data. Using these hot and cold input functions, we simulated TACs for the bound and free fractions separately for both cold and hot compounds using four differential equations. 19 We found that this set of parameters showed much slower displacement than that actually measured, i.e., the transition between equilibrium periods (Figure 3 ) was much slower than that found with the real data. We thus scaled k on and k off up by a factor of 10 in period 2 to match the measured curves. Note that this effect has been seen previously, where kinetics in the blocking state are accelerated compared with the tracer-only state. This can be explained by radioligand rebinding in a relatively isolated compartment referred to as the synaptic barrier, 29, 30 that the k off parameter estimated from the tracer-only part of the data was unreliable, or that an extra nonspecific compartment was needed (i.e., k 5 ≠0, k 6 ≠0 in Delforge's model 31 ). We then compared the ratio of cold/hot concentrations during the equilibrium periods to that predicted by the ratio of the cold/ hot infusion rates. Using the simulated curves in the cerebellum based on the four input functions, in equilibrium period 2, the discrepancy between the cold/hot ratio in plasma relative to cold/hot infusion rate was 8 ± 16%, and the difference of cold/hot ratio in free and bound compartments relative to input compartment was 11 ± 7% and 16 ± 13%, respectively. This suggests that equilibrium between cold and hot compounds was not quite attained, even though the % change/hour in the tracer level was small. It is likely that if we had allowed the cold infusions to last longer than 90 minutes, this discrepancy would have been reduced.
In the experimental design and data analysis, we ignored the impact of residual cold compound from cold infusion 1 clearing during cold infusion 2. We used the simulation described above to examine the potential bias by simulating studies with a 4:1 ratio of cold concentrations between the second and first cold infusions. To simulate this, the B/I input curve was used to generate a bolus curve using equation (5B) in Watabe et al, 32 from which the clearance phase after the end of cold infusion 1 could be calculated. The average V T during the third equilibrium period was overestimated by less than 1% by ignoring the clearance from cold infusion 1. Thus, the combination of rapid tracer clearance, the 4:1 ratio of cold infusion rates, and the high occupancy in third infusion stage caused this effect to be negligible.
In Table 2 , it is interesting to note that the K d estimated from the POOLED analysis did not fall between the K d values obtained from the individual K d analysis. Given the nonlinearity of equation (11) and the use of least squares fitting, this is certainly mathematically possible, especially if there are interanimal differences in K d . The POOLED K d value was quite close to that obtained from baboon B1, which may be due to the fact that the occupancies used in the B1 study were closer to the 50% occupancy point ( Table 1 ), so that baboon B1 provided more information about K d than baboon B2.
When analyzing data from the two animals separately, we estimated K d values of 1.52 and 3.14 nmol/L, based on the parametric fit. B max and V ND images of the two animals had similar distributions, but with different ranges. Further, the BP F values were more similar between the animals (Table 3 ). Although measurements of K d are typically quite variable, we investigated whether specific factors could have contributed to these differences. Both animals were female, but they varied in weight (B1 13.0 and B2 23.9 kg) and slightly in age (B1 8.1 and B2 8.9 years). Another potential difference lay in the fact that the designed occupancy levels were different for the two animals (Table 1) . Thus, based on the optimal design study, 33 the precision of parameter estimation depends on the experimental conditions. Measurement errors, such as errors associated with specific activity (SA), may introduce various magnitudes of errors in the K d and B max estimates. 18 For example, examination of equation (11) shows that a 10% positive bias in SA would introduce a 10% negative bias in both B max and K d . Variability in SA between experimental periods would introduce different errors in the parameters, depending on the occupancy levels in each period.
With knowledge of the in vivo K d , the mass dose to maintain tracer levels can be determined. Specifically, for a tracer dose, the free mass concentration in plasma M FP (nmol/L) should be less than a small fraction (α) of K d , i.e., to cause negligible occupancy.
To relate M FP to the injected mass dose D m (μg), we first determine the standard uptake value in plasma (SUV P ) at a suitable time (40 to 90 minutes after injection) from a human bolus study:
Here, D is the injected hot dose (kBq) and W is the subject weight (Kg). Equation (16) can be rearranged to determine M FP from D m , accounting for free fraction and molecular weight (MW):
Inserting (17) into (15) yields:
Setting α = 0.01 and MW = 488.4 g/mol, assuming human and baboon K d values are identical, and taking f P and SUV p values from preliminary human data (f P = 0.06, SUV p = 0.2), the suggested tracer dose limit for a bolus MK6577 injection for human studies is o1 μg/kg.
CONCLUSION
We developed a multi-infusion paradigm of radiolabeled and unlabeled MK6577 and an iterative linear/nonlinear alternating fitting method for the determination of a global estimate of in vivo K d , and to produce B max images for tracers without a reference region. Voxel-based analysis gave high quality parametric images. The in vivo K d was estimated to be 1.87 nmol/L for the GlyT1 tracer for 18 F-MK6577. The rank order of measured GlyT1 distribution (parametric B max ) was high in the brainstem (133 nmol/L), medium in the cerebellum (83 nmol/L), and low in the cortex (30 nmol/L), which agreed reasonably well with regional GlyT1 B max values determined in vitro. Allowing the nondisplaceable binding (V ND ) to vary between voxels provided a better description of the data. The proposed paradigm is suitable for 18 F-labeled tracers with fast kinetics.
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